跳至主要内容
临床试验/JPRN-UMIN000020940
JPRN-UMIN000020940已完成1 期

The safety and efficacy of autologous concentrated bone marrow grafting in the treatment of osteonecrosis and non-union - The safety and efficacy of autologous concentrated bone marrow grafting

Department of Orthopaedics Surgery, Faculty of Medicine, University of Tsukuba0 个研究点目标入组 20 人开始时间: 2016年2月9日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • A) a patient who is indicated to change the prescriptions of drugs for osteoporosis or steroid within 3 months (except dose reduction and withdrawal) B) a patient who is not candidates for Teriparatide C) a patient who is diabetes (HbA1C>9%) D) a patient who is arteriosclerosis obliterans E) a patient who is difficult to discontinue Warfarin F) Brinkman index>600 G) a patient who suffered cardiac infarction or brain infarction within 6 months H) a patient who suffered severe heart, liver, or renal dysfunction I) a patient who takes digitalis J) a patient who requires dialysis K) a patient who suffered or suspected malignancy within 5 years L) a patient who suffered hematological malignancy M) a patient who have 1 year to live N) a patient who suffered active infection O) systolic blood pressure < 90 mmHg within 2 weeks) P) Body weight < 40 kg (within 2 weeks) Q) a patient who suffered loss of marrow function (within 2 weeks) R) a patient who does not have voluntary consent S) a patient who is difficult to take informed consent in writing T) others

研究者

发起方
Department of Orthopaedics Surgery, Faculty of Medicine, University of Tsukuba

相似试验

The safety and efficacy of autologous concentrated... | 临床试验